4/A: Keros Therapeutics Director Amends SEC Filing to Disclose Indirect Shareholdings

Ran Nussbaum, a Director and 10% owner of Keros Therapeutics, Inc., has filed an amended Form 4 to correct the inadvertent omission of 155,262 indirectly held common shares.

Summary

• Ran Nussbaum, a Director and 10% owner of Keros Therapeutics, Inc. (KROS), filed an amended Form 4 (Form 4/A) to correct previous disclosures.
• The amendment addresses the inadvertent omission of indirect beneficial ownership of 155,262 shares of Keros Therapeutics common stock.
• These shares are held by Pontifax Late Stage Fund, L.P. ('Late Stage').
• Mr. Nussbaum, along with Pontifax Management 4 G.P. (2015) Ltd., may be deemed to share voting and dispositive power over these shares due to a strategic alliance agreement dated August 9, 2018.
• The omitted holdings were from prior Forms 4 filed on November 30, 2022, and June 6, 2025.
• The reporting person disclaims beneficial ownership of these shares except to the extent of their pecuniary interest, and the inclusion is not an admission of beneficial ownership for Section 16 purposes.

Sentiment

Score: 6

Explanation: The filing is a routine compliance amendment to correct a past oversight, which is a positive for transparency and regulatory adherence, but does not indicate new operational or financial performance, thus overall neutral to slightly positive.

Positives

• The filing demonstrates transparency and commitment to regulatory compliance by correcting previously omitted information.
• The disclosure provides a more complete and accurate picture of the beneficial ownership structure for investors and the market.

Negatives

• The initial inadvertent omission of indirect holdings indicates a past oversight in regulatory reporting.

Risks

• Potential minor compliance risk due to the initial inadvertent omission, though mitigated by the corrective filing.

Future Outlook

The document does not contain any forward-looking statements or guidance regarding the company's future operations or financial performance.

Industry Context

Form 4 filings are standard regulatory disclosures for company insiders, providing transparency on their trading activities and beneficial ownership. This amendment highlights the ongoing importance of accurate and timely reporting of beneficial ownership, especially for significant shareholders and directors, which is a common regulatory focus across all industries to ensure market integrity.

Corporate Governance

Related Party Transactions

• The indirect ownership of 155,262 shares is through Pontifax Late Stage Fund, L.P., where the reporting person (Ran Nussbaum) may be deemed to share voting and dispositive power. This structure, involving Pontifax entities and a strategic alliance agreement, constitutes a related party arrangement for beneficial ownership reporting.

Stakeholder Impact

• Shareholders: Benefit from increased transparency and accuracy of insider ownership disclosures, providing a clearer picture of who controls company stock.
• Regulatory Authorities: The correction demonstrates compliance with SEC reporting requirements, upholding regulatory standards.

Key Dates

Keywords

Keros Therapeutics, KROS, Ran Nussbaum, SEC Form 4/A, beneficial ownership, insider trading, Pontifax, common stock, director, 10% owner, compliance, disclosure